SSG
NERV icon

Summit Securities Group’s Minerva Neurosciences NERV Stock Holding History

Summit Securities Group’s Portfolio NERV Stock Details NERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-2,185
Closed -$179K – 235
2016
Q2 		$179K Buy
+2,185
New +$139K 0.1% 204

Other funds holding NERV

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
HCMT
Highland Capital Management (Texas) Dallas, Texas $39M AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Summit Securities Group's NERV Position: Q3 2016 in Review

Summit Securities Group sold out of Minerva Neurosciences (NERV) in Q3 2016, closing a stake of 2,185 shares — an estimated $179K sold.

Summit Securities Group first reported a position in NERV in Q2 2016 and held it in 1 quarter. The position peaked at $179K in Q2 2016. 67 funds tracked by Wall St. Rank hold NERV as of Q3 2016.

  • Summit Securities Group reported no remaining Minerva Neurosciences position as of Q3 2016 after selling out during the quarter.
  • Summit Securities Group sold 2,185 Minerva Neurosciences shares in Q3 2016, an estimated $179K.
  • Summit Securities Group first reported a position in Minerva Neurosciences in Q2 2016 and held it in 1 quarter.
  • Summit Securities Group's Minerva Neurosciences position peaked at $179K in Q2 2016.
  • 67 funds tracked by Wall St. Rank held Minerva Neurosciences as of Q3 2016.

Based on Summit Securities Group's 13F filing for Q3 2016, filed 7 Nov 2016.